Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 227-228

  Hotz, Christian ^a,b   Bourquin, Carole ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Cancer immunotherapy; Innate immunity; TLR tolerance; TLR7

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 10; INTERLEUKIN 6; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE CYCLE TREATMENT; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; NOTE; PRIORITY JOURNAL; SYSTEMIC THERAPY;

EID: 84885724042     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18169     Document Type: Note

References (10)

1. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31:318-23; http://dx.doi.org/10.1111/j.1524-4725.2005.31081
2. Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol 2009; 183:6078-86; http://dx.doi.org/10.4049/jimmunol.0901594
3. Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, et al. Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol 2010; 184:939-46; http://dx.doi. org/10.4049/jimmunol.0901245
4. Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 2011; 17:1765-75; http://dx.doi.org/10.1158/1078-0432.CCR-10-2672
5. Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14:856-64; http://dx.doi.org/10.1158/1078-0432.CCR-07-1938
6. Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother 2010; 59:1877-84; http://dx.doi.org/10.1007/s00262-010-0914-1
7. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010; 115:1949-57; http://dx.doi.org/10.1182/blood-2009-08-238543
8. Broad A, Kirby JA, Jones DE. Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferonbeta production. Immunology 2007; 120:103-11; http://dx.doi.org/10.1111/j.1365-2567.2006.02485.x
9. Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, et al. Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance. Cancer Res 2011; 71:5123-33; http://dx.doi.org/10.1158/0008-5472.CAN-10-3903
10. Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, et al. TLR4 Engagement during TLR3-Induced Proinflammatory Signaling in Dendritic Cells Promotes IL-10-Mediated Suppression of Antitumor Immunity. Cancer Res 2011; 71:5467-76; http://dx.doi.org/10.1158/0008-5472.CAN-10-3988